Search results for "Androgen receptor"

showing 10 items of 48 documents

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

2021

A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of androgen receptor pathway. Therefore, effective drugs against both CRPC and NEPC are needed. We have previously described a dual role of mast cells (MCs) in prostate cancer, being capable to promote adenocarcinoma but also to restrain NEPC. This finding suggests that a molecule targeting both MCs and NEPC cells could be effective against prostate cancer. Using an in silico drug repurposing approach, here we identify the antiepileptic drug levetiracetam as a potential candidate for this purpose. We found that the protein…

0301 basic medicineMaleLevetiracetammast cellsneuroendocrine differentiationNeuroendocrine differentiationCell DegranulationAndrogen deprivation therapyProstate cancer0302 clinical medicineTumor Cells CulturedImmunology and AllergySV2AOriginal ResearchMembrane Glycoproteinsdrug repurposingCell Differentiationprostate cancerGene Expression Regulation NeoplasticMatrix Metalloproteinase 9030220 oncology & carcinogenesisAdenocarcinomaAnticonvulsantsLevetiracetammedicine.druglcsh:Immunologic diseases. AllergyImmunologyAntineoplastic AgentsMice TransgenicNerve Tissue Proteins03 medical and health sciencesmedicineAnimalsHumanstumor microenvironmentmouse modelsHigh-grade prostatic intraepithelial neoplasiadrug repurposing; mast cells; mouse models; neuroendocrine differentiation; prostate cancer; tumor microenvironmentCell Proliferationbusiness.industryDrug RepositioningProstatic NeoplasmsNeoplasms Experimentalmedicine.diseaseCarcinoma Neuroendocrinedrug repurposing mast cells mouse models neuroendocrine differentiation prostate cancer tumor microenvironmentAndrogen receptorMice Inbred C57BL030104 developmental biologyCancer researchlcsh:RC581-607business
researchProduct

Am J Hum Genet

2019

ZMIZ1 is a coactivator of several transcription factors, including p53, the androgen receptor, and NOTCH1. Here, we report 19 subjects with intellectual disability and developmental delay carrying variants in ZMIZ1. The associated features include growth failure, feeding difficulties, microcephaly, facial dysmorphism, and various other congenital malformations. Of these 19, 14 unrelated subjects carried de novo heterozygous single-nucleotide variants (SNVs) or single-base insertions/deletions, 3 siblings harbored a heterozygous single-base insertion, and 2 subjects had a balanced translocation disrupting ZMIZ1 or involving a regulatory region of ZMIZ1. In total, we identified 13 point mutat…

0301 basic medicineMaleMicrocephaly[SDV]Life Sciences [q-bio]Developmental DisabilitiesAucunBiology030226 pharmacology & pharmacyTransactivation03 medical and health sciencesMiceNeurodevelopmental disorder0302 clinical medicineReportIntellectual DisabilityCoactivatormedicineGeneticsAnimalsHumansPoint MutationAlleleChildExomeGenetics (clinical)Alleles030304 developmental biologyGenetics0303 health sciencesPoint mutationCorrectionInfantSyndromemedicine.diseaseAndrogen receptor030104 developmental biologyChild PreschoolFemale030217 neurology & neurosurgeryTranscription Factors
researchProduct

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Nov…

2017

Abstract Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. Here, we evaluate the activity of darolutamide in enzalutamide-resistant castration resistant prostate cancer (CRPC) as well as in AR mutants detected in patients after treatment with enzalutamide, abiraterone, or bicalutamide. Darolutamide significantly inhibited cell growth and AR transcriptional activity in enzalutamide-resistant MR49F cells in vitro, and led to decreased tumor volume and serum prostate-specific antigen l…

0301 basic medicineMaleModels MolecularTime FactorsTranscription GeneticProtein ConformationProstate cancerchemistry.chemical_compoundMice0302 clinical medicineMolecular Targeted TherapyTumor BurdenDarolutamideReceptors Androgen030220 oncology & carcinogenesisBenzamidesmedicine.drugSignal Transductionmedicine.medical_specialtyBicalutamideUrologyPartial agonist03 medical and health sciencesStructure-Activity RelationshipIn vivoInternal medicineCell Line TumorNitrilesPhenylthiohydantoinmedicineAndrogen Receptor AntagonistsEnzalutamideAnimalsHumansCell ProliferationDose-Response Relationship DrugCell growthbusiness.industryProstatic Neoplasmsmedicine.diseaseXenograft Model Antitumor AssaysAndrogen receptor030104 developmental biologyEndocrinologychemistryDrug Resistance NeoplasmMutationCancer researchPyrazolesbusinessEuropean urology
researchProduct

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

2021

Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in comparison to phenotypically similar breast tumor subtypes: triple-negative invasive ductal carcinoma (TN-IDC) and hormone receptor-positive invasive lobular carcinoma (HR + ILC). All primary TN-ILCs registered in our database between 2000 and 2018 (n = 38) were compared to tumors from control groups, matched by stage and Elston/Ellis grade, with regard to clinical, pathologic, and immunohistochemical characteristics. A comparative molecular analy…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyReceptor ErbB-2Lobular carcinomaDNA Mutational AnalysisTriple Negative Breast NeoplasmsArticlePathology and Forensic Medicine03 medical and health sciencesBasal (phylogenetics)Phosphatidylinositol 3-Kinases0302 clinical medicineBreast cancerInternal medicinemedicineCarcinomaHumansskin and connective tissue diseasesSurvival analysisAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseAndrogen receptorbody regionsCarcinoma Lobular030104 developmental biologyPleomorphism (cytology)Receptors EstrogenReceptors Androgen030220 oncology & carcinogenesisInvasive lobular carcinomaMutationFemalebusinessModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer

2017

Crosstalk between the androgen receptor (AR) and other signaling pathways in prostate cancer (PCa) severely affects the therapeutic outcome of hormonal therapy. Although anti-androgen therapy prolongs overall survival in PCa patients, resistance rapidly develops and is often associated with increased AR expression and upregulation of the HER2/3-AKT signaling pathway. However, single agent therapy targeting AR, HER2/3 or AKT usually fails due to the reciprocal feedback loop. Previously, we reported that wedelolactone, apigenin, and luteolin are the active compounds in Wedelia chinensis herbal extract, and act synergistically to inhibit the AR activity in PCa. Here, we further demonstrated th…

0301 basic medicinenatural productsmedicine.drug_classPharmacologyurologic and male genital diseasesAntiandrogen03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineHER3HER2LNCaPMedicineEnzalutamidePharmacology (medical)Pharmacologybusiness.industrylcsh:RM1-950apoptosisprostate cancerWedelolactonemedicine.diseaseAndrogenanimal modelsAndrogen receptorlcsh:Therapeutics. Pharmacology030104 developmental biologychemistry030220 oncology & carcinogenesisHormonal therapybusinessFrontiers in Pharmacology
researchProduct

Heavy resistance exercise training and skeletal muscle androgen receptor expression in younger and older men

2010

Effects of heavy resistance exercise on serum testosterone and skeletal muscle androgen receptor (AR) concentrations were examined before and after a 21-week resistance training period. Seven healthy untrained young adult men (YT) and ten controls (YC) as well as ten older men (OT) and eight controls (OC) volunteered as subjects. Heavy resistance exercise bouts (5 × 10 RM leg presses) were performed before and after the training period. Muscle biopsies were obtained before and 1h and 48 h after the resistance exercise bouts from m.vastus lateralis (VL) to determine cross-sectional area of muscle fibers (fCSA) and AR mRNA expression and protein concentrations. No changes were observed in YC …

AdultMaleAgingmedicine.medical_specialtymedicine.drug_classClinical BiochemistryPhysical exerciseBiologyBiochemistryMuscle hypertrophyEndocrinologyReference ValuesInternal medicinemedicineHumansTestosteroneMuscle StrengthRNA MessengerMuscle Skeletalta315Molecular BiologyTestosteroneAgedPharmacologyReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingOrganic ChemistrySkeletal muscleResistance TrainingMiddle AgedAndrogenAndrogen receptorEndocrinologymedicine.anatomical_structureGene Expression RegulationReceptors AndrogenAgeingLean body massSteroids
researchProduct

Effects of resistance training on testosterone metabolism in younger and older men

2015

This study investigated the effects of resistance training (RT) on the metabolism of testosterone (T) in younger (n=5, 28±3yrs.) and older (n=8, 70±2yrs.) men. Experimental heavy resistance exercises (5×10RM leg presses) were performed before and after a 12-month of RT. No age differences were found in the production or metabolic clearance rate of T (determined by stable isotope dilution method), skeletal muscle androgen receptor content or serum LH concentrations due to acute or chronic RT. The T production capacity response to gonadotropin stimulation and the concentrations of the urinary T metabolites (androsterone and etiocholanolone) were lower in the older compared to younger men (p<0…

AdultMaleLuteinizing hormoneAgingmedicine.medical_specialtyta3111AndrosteroneBiochemistryMuscle hypertrophychemistry.chemical_compoundEndocrinologySex hormone-binding globulinInternal medicineEtiocholanoloneGeneticsmedicineHumansTestosteroneMuscle Skeletalta315ExerciseMolecular BiologyTestosteroneAgedEtiocholanoloneAndrosteronebiologyta1184Age FactorsResistance TrainingCell BiologyHypothalamic–pituitary–thyroid axisPatient Outcome AssessmentRenal EliminationAndrogen receptorEndocrinologychemistryReceptors AndrogenIsotope LabelingGnRHbiology.proteinLuteinizing hormoneHormonemedicine.drugExperimental Gerontology
researchProduct

Expression of hormonal receptors in osteosarcomas of the jaw bones: clinico-pathological analysis of 21 cases

2013

Background: Sexual hormones have an important role in many hormone-dependant tumors like breast and prostate carcinomas, and also a relationship has been found with bone metabolism and bone tumors. Some studies have demonstrated that the expression of hormonal receptors (HR) in osteosarcomas (OS) of long bones is associated with gender, histological grade, histological type, and possibly may be connection with pathogenesis and evolution. However, to our knowledge there are no studies of HR in osteosarcomas of craniofacial bones (OS-CF). Objectives: To assess the expression of hormonal receptors in OS-CF. Material and Methods: Twenty one cases of OS-CF were included in this study. Clinical o…

AdultMalePathologymedicine.medical_specialtyAdolescentmedicine.drug_classEstrogen receptorOdontologíaYoung AdultProgesterone receptormedicineHumansCraniofacialReceptorGeneral DentistryAgedOsteosarcomaOral Medicine and Pathologybusiness.industryResearchMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseJaw NeoplasmsCiencias de la saludAndrogen receptorReceptors EstrogenOtorhinolaryngologyReceptors AndrogenEstrogenUNESCO::CIENCIAS MÉDICASOsteosarcomaFemaleSurgeryReceptors ProgesteronebusinessProgressive disease
researchProduct

Cutaneous Lymphadenoma Is a Distinct Trichoblastoma-like Lymphoepithelial Tumor With Diffuse Androgen Receptor Immunoreactivity, Notch1 Ligand in Ree…

2021

The term "cutaneous lymphadenoma" was coined in this journal for an unusual lymphoepithelial cutaneous adnexal neoplasm, possibly with immature pilosebaceous differentiation. Some authors further proposed that cutaneous lymphadenoma was an adamantinoid trichoblastoma. However, although a hair follicle differentiation is widely accepted, the fact that this is a lymphoepithelial tumor is not appropriately explained by the trichoblastoma hypothesis. Our goal was to further clarify the phenotypic and genotypic features of cutaneous lymphadenoma in a series of 11 cases. Histologically, a lobular architecture surrounded by a dense fibrous stroma was present in all cases. The lobules were composed…

AdultMalePathologymedicine.medical_specialtySkin NeoplasmsCD30EGFRDNA Mutational Analysisadamantinoid trichoblastomaGene mutationBiologyStem cell markerT-Lymphocytes RegulatoryPathology and Forensic MedicineLymphocytes Tumor-Infiltratingandrogen receptormedicineBiomarkers TumorHumansReceptor Notch1Reed-Sternberg CellsAgedNotch1Jagged-1cutaneous lymphadenomaHigh-Throughput Nucleotide SequencingEpithelial CellsOriginal ArticlesMiddle Agedmedicine.diseaseHair follicleAdenolymphomaImmunohistochemistryAndrogen receptorErbB ReceptorsTrichoblastomamedicine.anatomical_structureReceptors AndrogenMutationIntraepithelial lymphocyteSurgeryFemaleAnatomyHair FollicleImmunostainingThe American journal of surgical pathology
researchProduct

Elevated endogenous testosterone concentrations potentiate muscle androgen receptor responses to resistance exercise.

2009

The purpose of this study was to determine the influence of endogenous circulating testosterone (T) on muscle androgen receptor (AR) responses to acute resistance exercise (RE). Six healthy men (26+/-4 years; 176+/-5 cm; 75.8+/-11.4 kg) performed a knee extension exercise protocol on two occasions separated by 1-3 weeks. Rest preceded one trial (i.e., control [CON] trial) and a high-volume upper-body RE protocol designed to increase circulating T preceded the other trial (i.e., high T [HT] trial). Serial blood samples were obtained throughout each trial to determine circulating T concentrations. Biopsies of the vastus lateralis were obtained pre-RE (REST), 10-min post-RE (+10), and 180-min …

AdultMalemedicine.medical_specialtyTime FactorsAnabolismmedicine.drug_classEndocrinology Diabetes and MetabolismRestClinical BiochemistryBiologyBiochemistryQuadriceps MuscleYoung AdultEndocrinologyInternal medicinemedicineHumansTestosteroneExercise physiologyReceptorMuscle SkeletalMolecular BiologyExerciseTestosteroneCell BiologyAndrogenAndrogen receptorEndocrinologyReceptors AndrogenArea Under CurveMolecular Medicinemedicine.symptomHormoneMuscle contractionThe Journal of steroid biochemistry and molecular biology
researchProduct